Effects of natural compounds and commercial antibiotics on Pseudomonas aeruginosa quorum sensing
Pseudomonas aeruginosa is a Gram-negative bacterium designated by the WHO as a critical priority microorganism due to its virulence, controlled by a quorum sensing (QS) system. QS is regulated through specific subsystems: LasI/LasR, RhlI/RhlR, and PQS/MvfR. Several natural compounds can inhibit t...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pontificia Universidad Javeriana
2022-12-01
|
| Series: | Universitas Scientiarum |
| Subjects: | |
| Online Access: | https://revistas.javeriana.edu.co/index.php/scientarium/article/view/35795 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Pseudomonas aeruginosa is a Gram-negative bacterium designated by the WHO as a critical priority
microorganism due to its virulence, controlled by a quorum sensing (QS) system. QS is regulated
through specific subsystems: LasI/LasR, RhlI/RhlR, and PQS/MvfR. Several natural compounds can
inhibit these QS mechanisms. In this study, we determined the effect of curcumin, reserpine, and
their mixtures with two commercial antibiotics (gentamicin and azithromycin) on P. aeruginosa QS
mechanisms: mvfR gene expression and the production of pyocyanin and rhamnolipids. Antibiotic
and natural compounds’ minimal inhibitory concentrations (MICs) were determined via microdilution assays. Gentamicin, azithromycin, curcumin, reserpine, and their mixtures exerted variable
effects on mvfR gene expression, as assessed via semi-quantitative RT-PCR assays. Curcumin, reserpine, and gentamicin inhibited mvfR gene expression better than azithromycin, and the mixtures
curcumin-gentamicin and reserpine-gentamicin outperformed gentamicin alone in inhibiting mvfR
gene expression and decreasing pyocyanin and rhamnolipids production, revealing the synergistic
effect of these mixture components. The mixtures of curcumin and gentamicin and reserpine and
gentamicin may become alternatives to complement or enhance conventional methods currently used
to treat P. aeruginosa infections. |
|---|---|
| ISSN: | 0122-7483 2027-1352 |